Biased Ligands. Better Drugs.

Oliceridine (TRV130)

The first μ receptor G protein Pathway Selective modulator (μGPS)

Phase Target Indication Lead
Optimization
Preclinical
Development
Phase
1
Phase
2
Phase
3
OwnershipCollaborator
Oliceridine (TRV130) Phase 3 Mu-receptor Moderate to
Severe Pain
intravenous Trevena Logo
TRV734 Phase 1 Mu-receptor Moderate to
Severe Pain
oral Trevena Logo
TRV250 Preclinical Development Delta-receptor Migraine oral Trevena Logo

Oliceridine (TRV130) was designed to optimize opioid receptor pharmacology using Trevena‚Äôs ABLE™ platform and is intended to deliver an improved analgesic profile compared to conventional intravenous opioids. Oliceridine is the first μ-receptor G protein pathway selective modulator, or "μGPS", and is in development for the management of moderate-to-severe acute pain where intravenous therapy is preferred.

In February 2016, the FDA granted Breakthrough Therapy status to olicerdine. This designation is granted by the FDA to new therapies intended to treat serious conditions and for which preliminary clinical evidence indicates that the drug may demonstrate substantial clinical improvement over available therapies.

View TRV130 Publications

Copyright © Trevena, Inc.